BioNTech acquires Vienna-based start-up PhagoMed
BioNTech SE has acquired PhagoMed GmbH, an Austrian start-up for precision antimicrobial treatments supported by the European Institute of Innovation and Technology (EIT). PhagoMed develops novel synthetic lysins to fight bacterial infections as an alternative to antibiotics. Lysins are produced by bacteriophages and can break down the cell walls of bacteria, thereby killing them. The advantage of lysins is that they are very precise, and therefore only kill specific groups of bacteria. PhagoMed’s powerful LysinBuilder platform can manufacture synthetic lysins with the potential to revolutionise the treatment of bacterial infections by leading up to an entirely novel class of targeted antibacterials.
“We are thrilled to partner with BioNTech to further advance our synthetic lysin technology to address pressing health challenges,” said Alexander Belcredi and Lorenzo Corsini, co-CEOs of PhagoMed. “We thank the team and our mentors at EIT Health for their support to help us refine our pipeline, platform and business model that enabled us to achieve our critical business goals in this short timeline.”
Read more here: https://eithealth.eu/news-article/phagomed-acquired-by-biontech/